Marshall Wace, LLP Pacira Bio Sciences, Inc. Call Options Transaction History
Marshall Wace, LLP
- $63.3 Billion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding PCRX
# of Institutions
286Shares Held
48.7MCall Options Held
156KPut Options Held
623K-
Black Rock Inc. New York, NY7.91MShares$226 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.11MShares$146 Million0.0% of portfolio
-
Frontier Capital Management CO LLC1.91MShares$54.8 Million0.55% of portfolio
-
State Street Corp Boston, MA1.9MShares$54.5 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.88MShares$53.8 Million0.09% of portfolio
About Pacira BioSciences, Inc.
- Ticker PCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 45,824,200
- Market Cap $1.31B
- Description
- Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...